## Lithium and Endocrine Dysfunction **Key Point:** Hypothyroidism is the most common endocrine side effect of lithium, occurring in 20–30% of patients on chronic therapy. ### Mechanism of Lithium-Induced Hypothyroidism 1. Lithium inhibits thyroid peroxidase (TPO) and iodine incorporation 2. Reduces thyroid hormone (T₃ and T₄) synthesis and release 3. Increases thyroid-stimulating hormone (TSH) via feedback 4. May trigger or unmask autoimmune thyroiditis 5. Results in overt or subclinical hypothyroidism **High-Yield:** Lithium-induced hypothyroidism is: - More common in **women** (female-to-male ratio ~3:1) - More frequent with **higher doses** and **longer duration** of therapy - Often **asymptomatic** in early stages (detected by TSH screening) - **Reversible** if lithium is discontinued early, but may persist ### Lithium Endocrine Side Effects Comparison | Endocrine Effect | Frequency | Mechanism | Clinical Significance | |---|---|---|---| | **Hypothyroidism** | 20–30% (most common) | ↓ TPO, ↓ T₃/T₄ synthesis | Requires levothyroxine; TSH monitoring | | **Hyperparathyroidism** | 5–10% | ↑ PTH secretion, ↑ Ca²⁺ reabsorption | Mild hypercalcemia; rarely symptomatic | | **Hyperthyroidism** | < 1% | Rare; thyroiditis | Usually transient | | **Hypogonadism** | Uncommon | Unclear mechanism | Not a primary lithium effect | **Clinical Pearl:** All patients starting lithium should have baseline TSH and free T₄ measured, then monitored every 6–12 months. If hypothyroidism develops, levothyroxine can be added without discontinuing lithium. **Mnemonic:** **LEND** = **L**ithium → **E**ndocrine (Hypothyroidism is the **H**ighest incidence).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.